Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement
Structure Therapeutics Inc.'s American depositary receipts (GPCR) jumped more than 90% premarket on Friday after the company announced positive results from an early-stage trial of a weight-loss treatment and a $300 million private placement. The company's oral GLP-1 receptor agonist, GSBR-1290, resulted in placebo-adjusted weight loss of up to 5% in healthy patients with obesity or overweight after 28 days, the company said in a release. Structure said it continues to plan the launch of a phase 2b study of the treatment in type 2 diabetes next year. The company on Friday also announced a $300 million private placement financing, with "participation from a number of large healthcare dedicated institutional and mutual fund investors." The proceeds will go toward accelerating GSBR-1290 development as well as other programs from the company's oral incretin franchise, Structure CEO Raymond Stevens said in a statement.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-29-23 0802ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst